Helen's most recent trade in Halozyme Therapeutics Inc. was a trade of 20,000 Common Stock done at an average price of $8.1 . Disclosure was reported to the exchange on Sept. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 156,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 136,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 176,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.70 per share. | 02 Sep 2025 | 16,288 | 737,131 (0%) | 0% | 73.7 | 1,200,393 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.63 per share. | 02 Sep 2025 | 10,500 | 733,719 (0%) | 0% | 74.6 | 783,636 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.54 per share. | 02 Sep 2025 | 9,900 | 743,819 (0%) | 0% | 73.5 | 728,006 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.22 per share. | 02 Sep 2025 | 9,500 | 744,219 (0%) | 0% | 74.2 | 705,090 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.33 per share. | 02 Sep 2025 | 7,800 | 736,019 (0%) | 0% | 74.3 | 579,751 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.15 per share. | 02 Sep 2025 | 3,412 | 733,719 (0%) | 0% | 74.1 | 252,990 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 75.22 per share. | 02 Sep 2025 | 2,300 | 733,719 (0%) | 0% | 75.2 | 173,015 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 72.49 per share. | 02 Sep 2025 | 300 | 753,419 (0%) | 0% | 72.5 | 21,746 | Common Stock |
| Mohawk Industries | Helen L Suzanne | Possible Member of Group | Sale of securities on an exchange or to another person at price $ 132.92 per share. | 22 Aug 2025 | 800 | 88,784 (0%) | 0% | 132.9 | 106,336 | Common Stock |
| Signet Jewelers | Helen E. McCluskey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2025 | 14 | 35,707 (0%) | 0% | 0 | Common Shares, par value $0.18 | |
| Everus Construction Group | Helena Mercedes Hernandez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2025 | 1,860 | 1,860 | - | 0 | Common Stock | |
| Mohawk Industries | Helen L Suzanne | Possible Member of Group | Sale of securities on an exchange or to another person at price $ 127.34 per share. | 19 Aug 2025 | 750 | 89,584 (0%) | 0% | 127.3 | 95,507 | Common Stock |
| Mohawk Industries | Helen L Suzanne | Possible Member of Group | Sale of securities on an exchange or to another person at price $ 129.57 per share. | 19 Aug 2025 | 750 | 90,334 (0%) | 0% | 129.6 | 97,177 | Common Stock |
| Citizens Northern Corp | Helen S. Santiago | Director | Other type of transaction at price $ 19.36 per share. | 15 Aug 2025 | 119 | 9,645 (0%) | 0% | 19.4 | 2,304 | Common Stock |
| Citizens Northern Corp | Helen S. Santiago | Director | Other type of transaction at price $ 19.00 per share. | 15 Aug 2025 | 1 | 118 (0%) | 0% | 19 | 19 | Common Stock |
| Citizens Northern Corp | Helen S. Santiago | Director | Other type of transaction at price $ 19.00 per share. | 15 Aug 2025 | 1 | 119 (0%) | 0% | 19 | 19 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 11 Aug 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 20,000 | 196,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 20,000 | 216,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 20,000 | 236,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 11 Aug 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 11 Aug 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 63.01 per share. | 11 Aug 2025 | 18,717 | 735,002 (0%) | 0% | 63.0 | 1,179,321 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.14 per share. | 11 Aug 2025 | 14,948 | 738,771 (0%) | 0% | 64.1 | 958,839 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 63.24 per share. | 11 Aug 2025 | 13,042 | 740,677 (0%) | 0% | 63.2 | 824,802 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.00 per share. | 11 Aug 2025 | 6,958 | 733,719 (0%) | 0% | 64.0 | 445,319 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.83 per share. | 11 Aug 2025 | 5,052 | 733,719 (0%) | 0% | 64.8 | 327,511 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 63.60 per share. | 11 Aug 2025 | 1,283 | 733,719 (0%) | 0% | 63.6 | 81,596 | Common Stock |
| Commvault Systems Inc | Martha Helena Bejar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 1,189 | 7,036 (0%) | 0% | 0 | Common Stock | |
| Mohawk Industries | Helen L Suzanne | Possible Member of Group | Sale of securities on an exchange or to another person at price $ 120.60 per share. | 28 Jul 2025 | 2,500 | 91,084 (0%) | 0% | 120.6 | 301,503 | Common Stock |
| Skillsoft Corp Ordinary | Helena Buonanno Foulkes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2025 | 20,306 | 0 | - | - | Restricted Stock Units | |
| Skillsoft Corp Ordinary | Helena Buonanno Foulkes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2025 | 20,306 | 20,306 | - | - | Phantom Stock | |
| Skillsoft Corp Ordinary | Helena Buonanno Foulkes | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2025 | 12,430 | 12,430 | - | - | Restricted Stock Units | |
| Eventbrite Inc Ordinary | Helen Riley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2025 | 5,976 | 231,547 (0%) | 0% | 0 | Class A Common Stock | |
| Shattuck Labs Inc | Helen M. Boudreau | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2025 | 33,150 | 33,150 | - | - | Stock Option (Right to Buy) | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 08 Jul 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 20,000 | 256,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 20,000 | 276,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 20,000 | 296,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 08 Jul 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 08 Jul 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.43 per share. | 08 Jul 2025 | 19,792 | 733,927 (0%) | 0% | 56.4 | 1,116,783 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 55.74 per share. | 08 Jul 2025 | 16,402 | 733,719 (0%) | 0% | 55.7 | 914,215 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 57.62 per share. | 08 Jul 2025 | 15,746 | 733,719 (0%) | 0% | 57.6 | 907,237 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.74 per share. | 08 Jul 2025 | 4,254 | 749,465 (0%) | 0% | 56.7 | 241,380 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 54.48 per share. | 08 Jul 2025 | 3,598 | 750,121 (0%) | 0% | 54.5 | 196,030 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 57.08 per share. | 08 Jul 2025 | 208 | 733,719 (0%) | 0% | 57.1 | 11,872 | Common Stock |
| Signet Jewelers | Helen E. McCluskey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 3,777 | 35,693 (0%) | 0% | 0 | Common Shares, par value $0.18 | |
| Hamilton Beach Brands Holding | Helen Butler Rankin | Member of a Group | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 1,610 | 178,424 (1%) | 0% | - | Class A Common Stock | |
| HysterYale Materials Handling | Butler Rankin Helen | Member of a Group | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 948 | 56,022 (0%) | 0% | 0 | Class A Common Stock | |
| Oxford Industries Inc | Helen Ballard Weeks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 3,354 | 20,735 (0%) | 0% | 0 | Common Stock | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 74 | 6,716 | - | - | Restricted Stock Units (Deferred Stock Award 2/18/25) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 71 | 6,529 | - | - | Restricted Stock Units (Deferred Stock Award 2/22/12) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 58 | 5,252 | - | - | Restricted Stock Units (Deferred Stock Award 2/27/13) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 55 | 5,046 | - | - | Restricted Stock Units (Deferred Stock Award 2/20/24) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 51 | 4,658 | - | - | Restricted Stock Units (Deferred Stock Award 2/24/16) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 48 | 4,364 | - | - | Restricted Stock Units (Deferred Stock Award 2/13/20) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 47 | 4,306 | - | - | Restricted Stock Units (Deferred Stock Award 2/24/23) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 45 | 4,093 | - | - | Restricted Stock Units (Deferred Stock Award 2/25/15) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 45 | 4,143 | - | - | Restricted Stock Units (Deferred Stock Award 2/26/14) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 36 | 3,292 | - | - | Restricted Stock Units (Deferred Stock Award 2/22/17) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 34 | 3,074 | - | - | Restricted Stock Units (Deferred Stock Award 2/11/21) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 32 | 2,918 | - | - | Restricted Stock Units (Deferred Stock Award 2/14/19) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 32 | 2,909 | - | - | Restricted Stock Units (Deferred Stock Award 2/15/18) | |
| Hillenbrand Inc | Helen W. Cornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 31 | 2,839 | - | - | Restricted Stock Units (Deferred Stock Award 2/10/22) | |
| Precigen Inc | Helen Sabzevari | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 500,000 | 500,000 | - | - | Restricted Stock Units | |
| Immix Biopharma Inc | Helen C. Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 33,000 | 33,000 | - | - | Stock Option (Right to Buy) | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 20 Jun 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 20,000 | 316,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 20,000 | 336,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 20,000 | 356,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 20 Jun 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 52.57 per share. | 20 Jun 2025 | 20,000 | 733,719 (0%) | 0% | 52.6 | 1,051,460 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 20 Jun 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 52.96 per share. | 20 Jun 2025 | 20,000 | 733,719 (0%) | 0% | 53.0 | 1,059,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 53.91 per share. | 20 Jun 2025 | 15,511 | 733,719 (0%) | 0% | 53.9 | 836,214 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 53.11 per share. | 20 Jun 2025 | 4,489 | 749,230 (0%) | 0% | 53.1 | 238,406 | Common Stock |
| PJT Partners Inc Ordinary | Helen T. Meates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 39 | 22,898 | - | - | Restricted Stock Units | |
| Organon Co | Helene D. Gayle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 23,904 | 62,702 | - | - | Phantom Stock | |
| Marqeta Inc - Ordinary Sha... | Helen Riley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 38,387 | 99,999 | - | 0 | Class A Common Stock | |
| Marqeta Inc - Ordinary Sha... | Helen Riley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 38,387 | 0 | - | - | Restricted Stock Units | |
| Abercrombie Fitch Co | Helen E. McCluskey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 2,089 | 2,869 | - | - | Restricted Stock Unit | |
| Abercrombie Fitch Co | Helen Vaid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 2,089 | 2,869 | - | - | Restricted Stock Unit | |
| NXP Semiconductors | Julie Helen Southern | Director, Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 1,035 | 1,035 | - | - | Restricted Stock Unit | |
| Abercrombie Fitch Co | Helen E. McCluskey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2025 | 780 | 34,750 (0%) | 0% | 0 | Class A Common Stock | |
| Abercrombie Fitch Co | Helen E. McCluskey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2025 | 780 | 2,089 | - | - | Restricted Stock Unit | |
| Abercrombie Fitch Co | Helen Vaid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2025 | 780 | 5,072 (0%) | 0% | 0 | Class A Common Stock | |
| Abercrombie Fitch Co | Helen Vaid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2025 | 780 | 2,089 | - | - | Restricted Stock Unit | |
| Rigetti Computing Inc | Helene Gail Sandford | Director | Sale of securities on an exchange or to another person at price $ 11.19 per share. | 10 Jun 2025 | 47,648 | 210,104 | - | 11.2 | 532,952 | Common Stock |
| Rigetti Computing Inc | Helene Gail Sandford | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 14,902 | 225,006 | - | 0 | Common Stock | |
| Eventbrite Inc Ordinary | Helen Riley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 79,051 | 225,571 (0%) | 0% | 0 | Class A Common Stock | |
| IO Biotech Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 35,144 | 35,144 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 28,500 | 28,500 | - | - | Option to purchase common stock | |
| Premier Inc - Ordinary Sha... | Helen M. Boudreau | Director | Sale of securities on an exchange or to another person at price $ 22.88 per share. | 30 May 2025 | 2,000 | 18,668 (0%) | 0% | 22.9 | 45,760 | Class A Common Stock |
| NXP Semiconductors | Julie Helen Southern | Director, Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 822 | 12,119 (0%) | 0% | 0 | Common Stock |